Healthcare Industry News: abdominal aortic aneurysm
News Release - April 12, 2007
World's First Endologix Powerlink System Procedures Performed with Visiflex SurePass Delivery SystemIRVINE, Calif.--(HSMN NewsFeed)--Endologix, Inc. (Nasdaq: ELGX ) today announced the first three successful implantations of the PowerlinkŪ endoluminal stent graft (ELG) incorporating the Visiflex SurePass Delivery System(TM). The Visiflex SurePass is the Company's next-generation delivery device that allows physicians continued guidewire access to the contralateral limb of the unibody Powerlink ELG device.
The first procedure was completed at William Beaumont Hospital in Royal Oak, Mich., and two additional procedures were completed at the Arizona Heart Hospital in Phoenix, Ariz.
- Venkatesh G. Ramaiah, M.D., Director of Vascular and Endovascular Research at the Arizona Heart Institute, reported, "The SurePass Delivery System further improves upon a delivery technology that is already state-of-the-art in terms of ease of deployment."
- Grayson Wheatley III, M.D., from the Arizona Heart Institute, remarked, "It exceeded my expectations and in this particular case facilitated access to a difficult contralateral limb in a tortuous anatomy."
- O. W. Brown, M.D., from the William Beaumont Hospital, commented, "The technology performed beyond my expectations and I believe the SurePass will further simplify and broaden the applications for Powerlink."
"This is a significant improvement to the Powerlink System's design with a focus on upgrading and simplifying the procedure, giving users greater confidence to expand the universe of treatable patients," said Paul McCormick, president and CEO of Endologix. "This is an example of what a company can accomplish with strong clinical collaboration and strength of purpose."
Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.